ANTX
AN2 Therapeutics, Inc. NASDAQ Listed Mar 25, 2022$4.70
-2.89%
vs $4.84
Mkt Cap $142.0M
52w Low $1.03
82.8% of range
52w High $5.46
50d MA $4.58
200d MA $2.44
P/E (TTM)
-4.3x
EV/EBITDA
—
P/B
2.7x
Debt/Equity
0.0x
ROE
-66.3%
P/FCF
-4.8x
RSI (14)
59.10
ATR (14)
$0.46
Beta
-1.32
50d MA
$4.58
200d MA
$2.44
Avg Volume
366.5K
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
1800 El Camino Real · Menlo Park, CA 94027 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.24 | -0.29 | -20.8% | 5.00 | -3.0% | -7.6% | -15.4% | +2.3% | -4.2% | -1.6% | — |
| Nov 12, 2025 | AMC | -0.23 | -0.31 | -34.8% | 1.18 | -5.9% | -4.2% | +0.9% | -1.8% | +0.0% | -3.6% | — |
| Aug 12, 2025 | AMC | -0.31 | -0.21 | +32.3% | 1.05 | +1.0% | +0.0% | +1.0% | +0.9% | +4.7% | +2.7% | — |
| May 13, 2025 | AMC | -0.26 | -0.35 | -34.6% | 1.18 | -1.7% | +0.8% | +3.4% | -1.6% | -1.7% | +0.0% | — |
| Mar 25, 2025 | AMC | -0.25 | -0.25 | +0.0% | 1.50 | -0.7% | +1.3% | -5.3% | -3.5% | -2.2% | +1.5% | — |
| Nov 13, 2024 | AMC | -0.37 | -0.43 | -16.2% | 1.01 | +2.0% | -1.0% | +0.0% | +0.0% | +6.0% | +22.6% | — |
| Aug 13, 2024 | AMC | -0.63 | -0.48 | +23.8% | 1.09 | -1.8% | -3.7% | -2.9% | -3.9% | +7.1% | +0.0% | — |
| May 14, 2024 | AMC | -0.61 | -0.56 | +8.2% | 2.31 | +1.3% | -1.7% | +0.0% | +0.0% | -1.8% | -2.7% | — |
| Mar 28, 2024 | AMC | -0.71 | -0.57 | +19.7% | 3.25 | +4.9% | +15.7% | -9.6% | -0.9% | -3.6% | -7.4% | — |
| Nov 9, 2023 | AMC | -0.63 | -0.65 | -3.2% | 15.40 | +0.9% | -7.1% | +4.8% | +6.3% | +0.8% | +2.3% | — |
| Aug 10, 2023 | AMC | -0.85 | -0.81 | +4.7% | 8.40 | -2.1% | +0.4% | +0.1% | +2.4% | +7.1% | +12.4% | — |
| May 11, 2023 | AMC | -0.68 | -0.79 | -16.2% | 5.06 | +2.0% | +0.6% | +7.1% | +36.0% | +11.7% | -5.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14 | Leerink Partners | Upgrade | Market Perform → Outperform | $9 | $4.31 | $4.64 | +7.7% | +7.7% | +2.4% | -5.7% | +1.6% | +0.9% |
| May 5 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.22 | $1.24 | +1.6% | -1.6% | -4.2% | +7.8% | -1.6% | -1.6% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $1.50 | $1.49 | -0.7% | +1.3% | -5.3% | -3.5% | -2.2% | +1.5% |
| Feb 25 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $1.14 | $1.13 | -0.9% | -2.6% | +1.8% | -1.8% | +2.7% | -1.8% |
| Feb 3 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.14 | $1.11 | -2.6% | -4.4% | +1.8% | +5.4% | -6.0% | -1.8% |
| Nov 19 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.00 | $1.03 | +3.0% | +6.0% | +22.6% | -5.4% | +8.9% | +3.7% |
| Nov 18 | TD Cowen | Downgrade | Buy → Hold | — | $1.00 | $1.00 | +0.0% | +0.0% | +6.0% | +22.6% | -5.4% | +8.9% |
| Aug 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.64 | $1.58 | -40.2% | -61.0% | +0.0% | +5.8% | -3.7% | -2.9% |
| Jul 3 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $2.13 | $2.20 | +3.3% | +27.2% | -3.0% | -4.9% | +2.0% | +2.0% |
| May 16 | Evercore ISI | Maintains | In Line → In Line | — | $2.27 | $2.30 | +1.3% | +0.0% | +0.0% | -1.8% | -2.7% | -2.3% |
| Apr 2 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $3.76 | $3.76 | +0.0% | -9.6% | -0.9% | -3.6% | -7.4% | +0.0% |
| Apr 1 | Oppenheimer | Maintains | Perform → Perform | — | $3.25 | $3.41 | +4.9% | +15.7% | -9.6% | -0.9% | -3.6% | -7.4% |
| Feb 13 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $5.10 | $5.00 | -2.0% | -23.5% | -1.0% | -0.3% | -5.5% | +1.6% |
| Feb 12 | Evercore ISI | Downgrade | Outperform → In Line | — | $20.00 | $5.34 | -73.3% | -74.5% | -23.5% | -1.0% | -0.3% | -5.5% |
| Feb 12 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $20.00 | $5.34 | -73.3% | -74.5% | -23.5% | -1.0% | -0.3% | -5.5% |
| Feb 12 | Oppenheimer | Downgrade | Outperform → Perform | — | $20.00 | $5.34 | -73.3% | -74.5% | -23.5% | -1.0% | -0.3% | -5.5% |
| Mar 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.82 | $10.05 | +2.3% | -1.9% | +2.5% | +0.4% | -9.9% | +0.0% |
| Nov 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $14.87 | $15.00 | +0.9% | -1.0% | -0.1% | -3.3% | -2.9% | -5.7% |
| Apr 19 | Evercore ISI | Maintains | Outperform → Outperform | — | $14.79 | $14.61 | -1.2% | -5.3% | +0.1% | +4.8% | -0.7% | +2.9% |
| Apr 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.79 | $14.61 | -1.2% | -5.3% | +0.1% | +4.8% | -0.7% | +2.9% |
| Apr 19 | TD Cowen | Maintains | Outperform → Outperform | — | $14.79 | $14.61 | -1.2% | -5.3% | +0.1% | +4.8% | -0.7% | +2.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 | Williams Sarah Joanne | Principal Accounting Officer | Sell | 265 | $4.43 | $1K | 66,583 | +3.19% | +1.56% |
8-K
AN2 Therapeutics, Inc. -- 8-K Filing
Jun 9
8-K
Unknown — 8-K Filing
ANTX established an at-the-market offering agreement with Jefferies, allowing flexible capital raises without shareholder approval, which could dilute existing shareholders but provides crucial funding flexibility.
Apr 9
8-K
Unknown — 8-K Filing
ANTX repriced underwater stock options with extended terms, allowing management retention without new dilution, which signals confidence but may disappoint shareholders unhappy with existing dilution.
Mar 20
8-K
Unknown — 8-K Filing
ANTX's advancement of epetraborole into Phase 2 testing signals confidence in its boron platform's commercial potential, but investors should monitor clinical trial results closely as the company remains pre-revenue and capital-dependent.
Mar 17
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
ANTX issued equity to ITS TRANSFER AG, likely diluting existing shareholders but potentially bringing strategic partnership value or capital infusion needed for operations.
Mar 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vivo Capital, Llc | 3,153,640 | $11M | New | Mar 2026 |
| 2 | Millennium Management | 2,222,502 | $8M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,011,078 | $3M | New | Mar 2026 |
| 4 | Woodline Partners Lp | 993,671 | $3M | Added | Mar 2026 |
| 5 | Stonepine Capital Management, Llc | 713,845 | $2M | Added | Mar 2026 |
| 6 | Ally Bridge Group (Ny) Llc | 526,315 | $2M | New | Mar 2026 |
| 7 | Bank Of Nova Scotia | 459,194 | $2M | — | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 393,702 | $1M | Added | Mar 2026 |
| 9 | Bank Of Montreal /can/ | 260,127 | $890K | Reduced | Mar 2026 |
| 10 | Renaissance Technologies Llc | 198,800 | $680K | Reduced | Mar 2026 |
| 11 | Citadel Advisors Llc | 155,239 | $531K | Added | Mar 2026 |
| 12 | Morgan Stanley | 459,540 | $524K | Added | Dec 2025 |
| 13 | Centiva Capital, Lp | 75,000 | $256K | New | Mar 2026 |
| 14 | Ubs Group Ag | 61,392 | $210K | Added | Mar 2026 |
| 15 | Peapod Lane Capital Llc | 59,854 | $207K | Reduced | Mar 2026 |
| 16 | Northern Trust Corp | 43,196 | $148K | — | Mar 2026 |
| 17 | Captrust Financial Advisors | 40,000 | $137K | — | Mar 2026 |
| 18 | Persistent Asset Partners Ltd | 38,155 | $130K | New | Mar 2026 |
| 19 | Hrt Financial Lp | 32,924 | $112K | New | Mar 2026 |
| 20 | Bnp Paribas Financial Markets | 30,078 | $103K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Market Fund | 59,000 | $202K | Mar 2026 |
| 2 | iShares Micro-Cap ETF | 53,165 | $182K | Mar 2026 |
| 3 | Fidelity Extended Market Index Fund | 114,783 | $126K | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 48,504 | $53K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 30,268 | $33K | Feb 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 13,988 | $15K | Feb 2026 |
Valuation
Market Cap
$142.0M
Enterprise Value
$84.0M
P/E (TTM)
-4.27x
Forward P/E
—
PEG Ratio
0.03x
P/B
2.68x
P/S
—
P/FCF
-4.76x
EV/EBITDA
—
Shares Out
30.2M
Financials (TTM)
Revenue
$0
Net Income
-$34.6M
EBITDA
-$35.8M
Free Cash Flow
-$29.8M
Op Cash Flow
-$29.8M
EPS Basic
$-1.16
EPS Diluted
$-1.10
EPS Forward
$-0.91
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$62.0M
Total Liab.
$8.9M
Total Equity
$53.1M
Cash
$58.0M
LT Debt
$0
Book Value/Sh
$1.76
Debt/Equity
0.00x
Current Ratio
6.87
Quick Ratio
6.87
Returns & Growth
ROE
-66.3%
ROA
-56.8%
ROIC
-71.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
+32.6%
Price Returns
2W
-1.4%
1M
+15.0%
3M
+40.3%
6M
+336.0%
12M
+361.0%
Technicals
52W High
$5.46
52W Low
$1.03
50d MA
$4.58
200d MA
$2.44
RSI (14)
59.10
ATR (14)
$0.46
Beta
-1.32
Avg Volume
367K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Apr 12, 2018
Analyst Price Targets
Consensus
$7.75
High
$22.00
Low
$2.00
Median
$3.50
Data updated apr 24, 2026 6:15pm
· Source: financialmodelingprep.com